RFA: Detecting Multiple Sclerosis Before the Onset of Neurological Deficits
The National MS Society is pleased to announce the release of a new Request for Applications focusing on Detecting Multiple Sclerosis Before the Onset of Neurological Deficits, intended to support research that advances our Pathways to Cures Roadmap.
A priority objective of the Roadmap is the early detection of MS prior to the accumulation of neurological deficits. This RFA is designed to solicit research to advance this objective. This RFA is open to both not-for-profit academic research institutes and for-profit commercial organizations around the world.
Purpose of this RFA
This RFA is intended to support knowledge generation that will eventually lead to early detection of MS at the individual level. The RFA does not include funds to start new MS cohorts; applicants are encouraged to utilize existing cohorts and associated datasets and biological samples. Applications should address critical knowledge gaps in our understanding of preclinical and prodromal phases of MS.
Applicants should possess an M.D., Ph.D. or equivalent and be considered eligible by their institution to apply for grant support. Postdoctoral fellows, residents and other trainees are not eligible to apply. Please see the RFA instructions or Society Policies and Procedures
for exceptions for project managers at for-profit institutions.
A brief pre-application is required to determine if a proposal is aligned with the objectives of the RFA. Potential applicants are strongly encouraged to consult with Society scientific staff prior to submitting a proposal (see contact information below). Upon review of pre-applications by staff, applicants proposing work that is aligned with the RFA objectives will be invited to submit full applications.
For more information about this RFA, please contact:
- Pre-applications will be accepted beginning: March 1, 2021
- Final deadline for pre-applications: 5 pm ET, April 23, 2021
- Final deadline for full applications: 5 pm ET, April 30, 2021
Director, Commercial Research
Vice President, Research